Amgen says drug combo cuts death risk 58% in aggressive lung cancer

· Health · United States

Amgen said a drug from its pipeline could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca, cutting the risk of death by 58% in the study. The data could support a new combination treatment for a hard-to-treat cancer type. Full trial details were not provided in the report.

Why it matters：Improved survival data in a hard-to-treat cancer could change treatment standards and sharpen competition in oncology combinations.

Key points

  • The combination cut death risk by 58% in the study.
  • It adds an Amgen drug to an AstraZeneca immunotherapy.
  • The cancer type is described as aggressive.

Sources (original reporting)

More stories from this day